JP4738464B2 - Adiponectin secretion promoting food and drink - Google Patents

Description

  The present invention relates to an adiponectin secretion promoting food and drink that promotes adiponectin secretion and an adiponectin secretion promoter.

Adiponectin is one of the adipocytokines secreted from adipocytes, and it has been revealed that it plays an important role in energy metabolism by promoting fat burning and sugar utilization in the liver and skeletal muscle. Adiponectin is usually present in blood in an amount of 5 to 30 μg / ml, but it is known that the secretion amount of adiponectin decreases when fat cells are enlarged. The decrease in adiponectin is considered to be one of the causes of lifestyle-related diseases associated with visceral fat accumulation, and in fact, it has been reported that the blood concentration of adiponectin is significantly decreased in patients with coronary artery disease and patients with diabetes. (Non-Patent Documents 1 and 2).
In addition, adiponectin acts on the suppression of proliferation of vascular smooth muscle cells, the suppression of adhesion of monocytes to endothelial cells, the decrease in phagocytic ability of macrophages, and has an anti-arteriosclerotic effect (Non-patent Documents 3 and 4). It has been reported that insulin resistance is improved (Non-patent Documents 5 and 6).
Therefore, adiponectin is an important key factor in reducing the risk of metabolic syndrome upstream of arteriosclerosis and various lifestyle-related diseases, and it promotes adiponectin secretion endogenously by external stimulation. Therefore, it is estimated that these diseases can be prevented and treated.

  So far, thiazolidine derivatives, which are insulin resistance improving drugs, are known as compounds that promote the secretion of adiponectin in adipocytes (Non-patent Document 7). However, since thiazolidine derivatives develop edema due to an increase in circulating plasma volume in a short period of time and have side effects such as the development of heart failure, concerns over long-term use have been pointed out. In addition, since it is mainly used for the purpose of treatment of patients in medical institutions, it cannot be widely applied from the primary prevention of the disease to the treatment of severely ill people through the secondary prevention. Therefore, there has been a demand for a material derived from a natural product that does not have the side effects found in ethical drugs and can be consumed on a daily basis.

  From such a point of view, natural ingredients having an adiponectin secretion promoting action have been actively searched, and for example, fermented tea (Patent Document 1), ergosterol (Patent Document 2), and the like have been reported. However, they do not exhibit sufficiently strong activity as compared with thiazolidine derivatives, and the actual situation is that a satisfactory effect has not yet been obtained.

On the other hand, it is known that propolis contains various antioxidants. For example, artepilin C, which is one of them, has been reported to have antitumor action and antibacterial action. In addition, glucosamines, a kind of amino sugar obtained by degrading chitin contained in shells such as crab and shrimp, and chondroitin sulfate, a kind of acidic mucopolysaccharide contained in cartilage, all improve arthritis. It has been reported to have an action (Non-patent Document 8).
However, it is not known at all how an adiponectin is affected by combining an antioxidant such as artepilin C, corosolic acid, resveratrol, isoflavone, and glucosamines and / or chondroitin sulfate. .
JP 2004-315379 A JP 2008-63293 A Ouchi N. et al., Circulation 100, 2473-2476, 1999 Hotta K. et al., Arterioscler Thromb Vasc Biol 20, 1595-1599, 2000 Ouchi N. et al., Circulation 103, 1057-1063, 2001 Arita Y. et al., Circulation 105, 2893-2898, 2002 Yamauchi T. et al., Nat Med 7, 941-946, 2001 Berg AH. Et al., Nat Med 7, 947-953, 2001 Koji Hasegawa et al., 51st Annual Meeting of the Diabetes Society President Annual Poster IP-248, 2008 Sasamoto, et al., New drugs and clinical practice, 52, 301-312, 2003

  The present invention has been made in view of the conventional situation as described above, and it is an object to provide a food and drink for promoting adiponectin secretion and an adiponectin secretion promoter having high safety and excellent adiponectin secretion promoting action. To do.

  As a result of intensive studies to solve the problem, the present inventor has found that glucosamines and chondroitin sulfate alone do not promote adiponectin secretion, but when combined with an antioxidant, it is surprisingly anti-oxidant. It has been found that the adiponectin secretion promoting action of a substance is additively and synergistically enhanced and the adiponectin secretion efficiency in blood is further enhanced as compared with an antioxidant alone, and the present invention has been completed.

That is, this invention solves the said subject by the foodstuff for adiponectin secretion promotion characterized by containing an antioxidant substance, glucosamines, and / or chondroitin sulfate.
Moreover, this invention solves the said subject with the adiponectin secretion promoter characterized by using as an active ingredient an antioxidant substance and glucosamines and / or chondroitin sulfate.

  The food / beverage product or pharmaceutical product of the present invention has an adiponectin secretion-enhancing action intrinsically by combining an antioxidant and a joint composition, and exhibits an excellent adiponectin secretion-promoting action that has never been achieved. It is useful for the primary prevention and improvement of various lifestyle-related diseases such as arteriosclerosis, type 2 diabetes, hypertension and the metabolic syndrome located upstream thereof, which is thought to be useful to increase adiponectin secretion clinically. It is. Moreover, since the antioxidant substance, glucosamines, and chondroitin sulfate used in the present invention are highly safe, they can be blended in food and drink and continuously ingested.

The antioxidant substance used in the present invention is not particularly limited as long as it has antioxidant activity. The antioxidant activity of the substance can be examined by a known method, for example, by the 1,2-diphenyl-2-picrylhydrazyl (DPPH) method. Specifically, the stable DPPH radical has a peak at 520 nm, but the peak value at 520 nm is reduced by adding an antioxidant to the stable DPPH radical.
It can also be measured by the 2% vanillin / hydrochloric acid / methanol solution method. That is, the peak value at 500 nm is increased by adding an antioxidant to the reagent. This is obtained from an increase change record of the peak value at 500 nm.

Examples of the antioxidant include corosolic acid, resveratrol, isoflavone, artepiline C, 3,4-dihydroxy-5-prenylcinnamic acid, quercetin, kaempferide, p-coumaric acid, 4-dihydrocinnamoyloxy-3- Flavonoids, carotenoids, vitamins, and other antioxidants such as prenylcinnamic acid, propolis, astaxanthin, lycopene, anthocyanin, proanthocyanidins, catechins, isorhamnetin, kaempferol, rutin, coenzyme Q10, vitamin E (tocopherol), calcium ascorbate Examples thereof include substances having activity. These may be used alone or in combination of two or more.
The content of the antioxidant in the food / beverage product or pharmaceutical product of the present invention is not particularly limited, but is preferably 0.001 to 40% by mass, particularly preferably 0.003 to 30% by mass, and more preferably 0.004 to 20% by mass.

Antioxidants can be obtained by known organic chemical synthesis methods, extraction from natural products, callus, etc., and further combining organic chemical synthesis methods as necessary.
The extraction is performed by impregnation with a solvent at room temperature or in a heated state, or by using a distillation method such as steam distillation in addition to solvent extraction performed using an extraction device such as a Soxhlet extractor, and carbon dioxide gas. A supercritical extraction method performed in a critical state or a pressing method for obtaining an extract by pressing can be used.

  Antioxidants obtained by the above synthesis and extraction may be roughly purified as long as they meet the standards acceptable on pharmaceuticals or foods and exhibit the effects of the present invention. The purity of these compounds and extracts may be increased by appropriately combining known separation and purification methods. Examples of the purification means include organic solvent precipitation, centrifugation, ultrafiltration membrane, high performance liquid chromatograph, column chromatograph and the like.

  In the present invention, a natural product or callus containing these antioxidants or their precursors, or an extract thereof may be used as it is. The extract may be used as a diluted solution obtained by diluting the extract with an appropriate solvent, or may be a concentrated extract, a dry powder, or a paste.

For example, propolis includes artepilin C, 3,4-dihydroxy-5-prenylcinnamic acid, quercetin, kaempferide, p-coumaric acid and 4-dihydrocinnamoyloxy-3-prenylcinnamic acid. In, propolis can be used as an antioxidant as it is.
Propolis is also referred to as bee ani and is a mixture of plant shoots and exudates collected by bees, tree sap, pollen and beeswax, and is a resinous solid mass. Propolis may be derived from any locality / plant. Propolis can be used in the form of a raw mass powder, its powder suspension, its extract, and a more active fraction (component) obtained by further separation and purification. For example, it can be obtained from Biomedix Co., Ltd. as a commercial product.

  In addition, banaba leaves and loquat leaves contain corosolic acid, and in the present invention, these extracts can be used as antioxidants. For example, “1% loquat leaf extract” (Tokiwa Plant Chemistry Laboratory) is commercially available as an extract of loquat leaves.

  Berries such as bilberry and blueberry, purple grapes and the like contain anthocyanins, and in the present invention, these extracts can be used as antioxidants. For example, “Bilberry Extract 25” (Tama Biochemistry) is commercially available as an extract of bilberry.

  Grape peels and seeds, pine bark, peanut seed coat and the like contain proanthocyanidins and resveratrol. In the present invention, these extracts can be used as antioxidants. For example, “Red Wine Extract” (Oryza Oil, Mediens), “French Coastal Pine Bark Extract” (Toyo Shinyaku, Tradepia), and “Peanut Seed Extract” (Tokiwa Plant Chemistry Laboratory) are commercially available.

  The rough leaves and onion epidermis contain quercetin, and the ginkgo leaves contain quercetin, isorhamnetin, kaempferol and rutin. In the present invention, these extracts can be used as antioxidants. For example, “Rafuma leaf extract” is commercially available as an extract of Raffma leaf, and “Ginkgo biloba extract” (Tama Biochemistry) is commercially available as an extract of Ginkgo biloba.

  Green tea contains catechins, and this extract can be used in the present invention. For example, “green tea extract” (Tama Biochemistry) is commercially available.

  In the present invention, from the viewpoint of promoting adiponectin secretion, corosolic acid, resveratrol, isoflavone, artepillin C, 3,4-dihydroxy-5-prenylcinnamic acid, quercetin, kaempferide, p-coumaric acid, 4-Dihydrocinnamoyloxy-3-prenylcinnamic acid, propolis, astaxanthin, lycopene, anthocyanin, proanthocyanidin are preferably used, especially corosolic acid, resveratrol, isoflavone, artepiline C, 3,4-dihydroxy-5- It is preferable to use prenylcinnamic acid and propolis.

Artepilin C is 4-hydroxy-3,5-diprenyl cinnamic acid, and any of E form, Z form or a mixture thereof can be used.
The content of artepilin C in the food or drink or pharmaceutical product of the present invention is preferably 0.1 to 6% by mass, particularly preferably 0.2 to 4% by mass, from the viewpoint of promoting adiponectin secretion.

  In addition, the content of 3,4-dihydroxy-5-prenylcinnamic acid in the food / beverage product or pharmaceutical of the present invention is preferably from 0.1 to 2% by mass, particularly preferably from 0.1 to 1% by mass, from the viewpoint of promoting adiponectin secretion. . In addition, the content of propolis is preferably 1 to 10% by mass, and particularly preferably 1.5 to 5% by mass, from the viewpoint of promoting adiponectin secretion and usability. The content of corosolic acid is preferably 0.003 to 0.04% by mass, particularly preferably 0.004 to 0.02% by mass, from the viewpoint of promoting adiponectin secretion. The content of resveratrol is preferably 0.05 to 0.5% by mass, particularly preferably 0.1 to 0.3% by mass, from the viewpoint of promoting adiponectin secretion.

Isoflavone is a compound having an isoflavone skeleton. , Acetylglycitin, and their metabolites can be used. These isoflavones can be used alone or in combination of two or more, but it is preferable to use one or more selected from daidzein, genistein and these glycosides. In addition, isoflavones are not particularly limited, and those derived from plants such as legumes, roses, iridaceae, mulberry, and amaraceae can be used, but those derived from soybeans are preferably used. Isoflavones are, for example, “Isomax AG40”, which is mainly composed of daidzein, and “Isomax 80”, which is mainly composed of genistein (both are Joban Plant Chemistry Laboratories). These can also be mixed and used as appropriate.
From the viewpoint of promoting adiponectin secretion, the content of isoflavone in the food or drink or pharmaceutical product of the present invention is preferably 0.4 to 4% by mass, particularly preferably 0.5 to 3% by mass as the total aglycone.

The glucosamines used in the present invention are a kind of amino sugar widely distributed in the living body, and can be obtained by enzymatic treatment, hydrolysis, microbial fermentation, chemical synthesis, etc. of chitin obtained from shells such as crabs and shrimps. . Examples of glucosamines include glucosamine, derivatives thereof, and salts thereof. Examples of the glucosamine derivative include N-acetylglucosamine, N-methyl-L-glucosamine and the like. The salt is not particularly limited as long as it is a pharmacologically acceptable salt. For example, inorganic acid salts such as hydrochloride, sulfate, and phosphate; acetate, citrate, gluconate, apple And organic acid salts such as acid salts and succinic acid salts. These glucosamines can be used alone or in combination of two or more.
In the present invention, N-acetylglucosamine and glucosamine hydrochloride are preferably used from the viewpoint of promoting adiponectin secretion, and N-acetylglucosamine is particularly preferably used.
As the N-acetylglucosamine, for example, the trade name “Marine Sweet YSK” (Yaizu Suisan Chemical Co., Ltd.) can be used.
Glucosamine hydrochloride is commercially available from Koyo Chemical, for example.

  The content of the glucosamines in the food or drink or pharmaceutical product of the present invention is preferably 10 to 90% by mass, particularly preferably 20 to 80% by mass, from the viewpoint of the synergistic effect of the adiponectin secretion promoting action and cost. 25-70 mass% is preferable.

Chondroitin sulfate used in the present invention is a kind of acidic mucopolysaccharide that is abundant in cartilage tissues of animals, and it can be extracted from cartilage of fish such as shark and ray. Chondroitin sulfate may be a salt, and the salt is not particularly limited as long as it is a pharmacologically acceptable salt. For example, alkali metal salts such as sodium salt and potassium salt; alkali such as calcium salt and magnesium salt Examples include earth metal salts; organic amine salts such as ammonium salts, triethanolamine salts, and triethylamine salts; and basic amino acid salts such as lysine salts and arginine salts. Of these, alkali metal salts are also preferable, and calcium salts are more preferable than sodium salts. Chondroitin sulfate can be obtained as a commercial product, for example, from Nippon Biocon for porcine cartilage, Maruha Nichiro for costal cartilage, and Marukyo Biofoods for ray cartilage.
The content of chondroitin sulfate in the food / beverage product or pharmaceutical product of the present invention is preferably 5 to 80% by mass, particularly preferably 5 to 70% by mass, from the viewpoint of a synergistic effect of adiponectin secretion promoting action and cost. 6-60 mass% is preferable.

  In order to enhance the adiponectin secretion-promoting action, the food / beverage product or pharmaceutical of the present invention preferably further contains one or more selected from collagen, cats claw, and royal jelly.

  Collagen is the main protein of connective tissues of animals, and can be obtained from mammals such as cattle and pigs; birds such as chickens; cartilage tissues such as sharks and fish such as rays, skin, and dermis layer. As the collagen, a heat-denatured or non-denatured type II collagen-containing portion or a hydrolyzate thereof is preferably used. For example, collagen peptide “C-mucolla” containing 30% heat-denatured type II collagen (Nippon Ham Co., Ltd.), collagen containing 25% non-denatured type II collagen (deleted peptide) “UC-II” (inter health), etc. Can be used.

  The content of collagen in the food / beverage product or pharmaceutical product of the present invention is preferably 0.02 to 30% by mass, particularly preferably 0.03 to 20% by mass, from the viewpoint of the synergistic effect of promoting adiponectin secretion.

  Cats Claw (Uncaria Tomentosa) is a Peruvian native Rubiaceae plant that can be used as it is or after pre-treatment such as drying, cutting, crushing, and pulverizing, and then using polar solvents such as water and alcohols. And a fraction (component) having a higher activity obtained by further separation and purification. In the extraction, any part of the plant can be used, but bark is preferably used. For the extract, the obtained fraction may be used as it is, may be used as a diluted solution diluted with an appropriate solvent, or may be a concentrated extract, a dry powder, or a paste. Cats claw extract powder can be obtained as a commercial product from the Imperial Research Institute of Pharmaceutical Sciences, Joban Plant Chemistry Laboratory, etc.

  From the viewpoint of the synergistic effect of the adiponectin secretion promoting action, the content of cat's claw in the food or drink or pharmaceutical product of the present invention is preferably 0.02 to 0.3% by mass, particularly preferably 0.04 to 0.2% by mass, as the total oxindole alkaloid.

Royal jelly is a jelly-like substance secreted from the throat gland by the bee worker bee as food for the queen bee. As the royal jelly, commercially available raw royal jelly, dried royal jelly and the like, which are generally commercially available as food and drink and pharmaceutical raw materials, can be arbitrarily used.
The content of the royal jelly in the food / beverage product or pharmaceutical product of the present invention is preferably 10 to 80% by mass, particularly preferably 20 to 60% by mass, from the viewpoint of the synergistic effect of the adiponectin secretion promoting action.

In the foods and beverages and pharmaceuticals of the present invention, in addition to the above components, various vitamins such as vitamin A, vitamin B ₁ , vitamin B ₂ , biotin, pantothenic acid, nicotinic acid, folic acid, etc., as necessary, various minerals Other nutrients such as hyaluronic acid, dietary fiber, polyunsaturated fatty acids, ginseng extract, garlic extract, AKBA (3-O-acetyl-keto-β-boswellic acid), white willow extract, methylsulfonium methane Etc. can be appropriately added and blended. Among these, it is preferable to add ginseng extract, AKBA (3-O-acetyl-keto-β-boswellic acid), and white willow extract from the viewpoint of enhancing adiponectin secretion promotion, especially 3-O-acetyl- It is preferable to add keto-β-boswellic acid.

  The content of ginseng extract in the food and drink or the pharmaceutical of the present invention is 1 to 20% by mass; the content of AKBA (3-O-acetyl-keto-β-boswellic acid) is 0.5 to 2% by mass; The content of the extract is preferably 1 to 6% by mass as salicin from the viewpoint of the synergistic effect of the adiponectin secretion promoting action.

  The food / beverage products or pharmaceuticals of the present invention exhibit an excellent adiponectin secretion promoting action, as shown in the examples below, in which the antioxidant adiponectin secretion promoting action is intrinsically enhanced by the joint composition. Therefore, the pharmaceutical agent of the present invention has various diseases considered useful for increasing adiponectin secretion, for example, various lifestyle-related diseases such as arteriosclerosis, type 2 diabetes, hypertension, and metabolic syndrome located upstream thereof. It can be used as a prophylactic or ameliorating agent and can further be used to formulate these. In addition, the food or drink or pharmaceutical product of the present invention is a food that has the concept of preventing or improving various lifestyle-related diseases such as arteriosclerosis, type 2 diabetes, hypertension and the metabolic syndrome located upstream thereof, and displays that fact. It can be applied to functional foods, foods for the sick, and foods for specified health use.

The form of the food or drink in the present invention is not particularly limited, but is preferably a functional food that promotes health. Examples of the form of food and drink include supplement types (powder, granules, tablets, fine granules, chewable tablets, film-coated tablets, dragees, drinks, soft capsules, hard capsules), drink types (drinks, jelly) And the like, and a carrier such as an excipient can be appropriately mixed according to the dosage form, and can be produced according to a conventional method.
In addition, preservatives, colorants, sweeteners, antioxidants, thickening stabilizers, emulsifiers, seasonings, preservatives, and other food additives, natural products, and the like are appropriately added to such foods and drinks. Can do.

  In addition, the dosage form of the pharmaceutical is not particularly limited. For example, chewable tablets, powders, granules, tablets, fine granules, film-coated tablets, sugar-coated tablets, drinks, soft capsules, hard capsules, jelly agents, liquid agents Orally administered preparations such as pharmaceutically acceptable carriers, such as excipients, disintegrants, binders, lubricants, diluents, buffers, etc. It can be mixed with an agent, lubricant, emulsifier, dispersant, stabilizer, solubilizer, etc., mixed, diluted or dissolved as appropriate, and manufactured according to a conventional method.

  When the food or drink or pharmaceutical of the present invention is applied to, for example, humans, for example, in the case of propolis-based artepilin C, the intake amount is usually 5 to 300 mg / day for an adult (body weight 50 kg). It is preferably applied so as to be 10 to 200 mg / day. In addition, the intake of 3,4-dihydroxy-5-prenylcinnamic acid in normal adults is 5 to 100 mg / day, preferably 5 to 50 mg / day; the intake of quercetin in normal adults is 10 to 400 mg / day, Preferably 20 to 200 mg / day; kaempferide intake in normal adults is 10 to 300 mg / day, preferably 20 to 200 mg / day; p-coumaric acid intake in normal adults is 20 to 500 mg / day, preferably 50-200 mg / day; it is preferable to apply 4-dihydrocinnamoyloxy-3-prenylcinnamic acid so that the normal adult intake is 10-1000 mg / day, preferably 50-300 mg / day. . Furthermore, since the above components are contained in propolis, it is preferable to apply 20 to 500 mg / day of the propolis ethanol-extracted powder as an intake amount for normal adults.

  Moreover, loquat leaf extract (containing 1% corosolic acid) is 20 to 200 mg / day, preferably 20 to 100 mg / day; red wine extract containing 5% resveratrol is 1 to 15 mg / day, preferably 1 to 5 as resveratrol. 10 mg / day; isoflavone is 20-200 mg / day, preferably 30-150 mg / day as total aglycone; lycopene is 5-100 mg / day, preferably 10-80 mg / day; astaxanthin is 0.5-30 mg / day, preferably 1-20 mg / day; bilberry extract as anthocyanin 15-180 mg / day, preferably 20-150 mg / day; French coast pine bark extract (containing 60% or more proanthocyanidins) is 10-100 mg / day, preferably 20-80 mg Green tea extract is 100 to 1500 mg / day, preferably 150 to 1000 mg / day as catechins; Rahma leaf (containing 4% total flavonol) is 10 to 100 mg / day, preferably 15 to 80 mg / day; Peanut seed coat extract Is proanthocyanidins 50-250 mg / day, preferably 70-200 mg / day; Ginkgo biloba extract is 20-600 mg / day, preferably 25-400 mg / day, as total flavonol; Coenzyme Q10 is 30-1200 mg / day, preferably 30-1000 mg / Day; calcium ascorbate is preferably applied in an amount of 50 to 2000 mg / day, preferably 50 to 1500 mg / day.

  The intake of glucosamines and chondroitin sulfate can be determined by the above-mentioned blending ratio according to the intake of antioxidants, but from the viewpoint of safety and effectiveness, the intake in adults is usually glucosamines Is preferably applied so as to be 50 to 5000 mg / day, preferably 50 to 3000 mg / day, and chondroitin sulfate is 50 to 50000 mg / day, preferably 50 to 3000 mg / day as the mass of the portion not containing the protein portion. It is preferable to apply as follows.

  Collagen, cat's claw and royal jelly can determine the intake amount according to the above-mentioned blending ratio according to the intake amount of the antioxidant, but the intake amount is usually 30% heat-denatured type II collagen collagen peptide in adults 40 to 5000 mg / day, preferably 50 to 3000 mg / day; collagen containing 25% non-denatured type II collagen is 5 to 100 mg / day, preferably 10 to 80 mg / day, and cats claw is 2 to 6 mg as total indole alkaloid / Day, preferably 2 to 4 mg / day; Royal jelly is preferably applied at 50 to 15,000 mg / day, preferably 100 to 10,000 mg / day.

  In addition, ginseng extract, AKBA (3-O-acetyl-keto-β-boswellic acid), and white willow can determine their intake according to the above-mentioned mixing ratio according to the intake of antioxidants. However, ginseng extract is 50-1000 mg / day, preferably 60-800 mg / day; AKBA (3-O-acetyl-keto-β-boswellic acid) is 20-90 mg / day, preferably 30-75 mg / day, It is preferable to apply white willow as salicin at 60 to 300 mg / day, preferably 70 to 200 mg / day.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated concretely, this invention is not limited at all by these.

[Raw materials] The following raw materials were used.
・ Biwa leaf extract (containing 1% corosolic acid), Bilberry extract: Joban Plant Chemistry Laboratory ・ Artepilin C, 3,4-dihydroxy-5-prenylcinnamic acid, quercetin, kaempferide, p-coumaric acid, 4-dihydrocinnamoyl Oxy-3-prenylcinnamic acid, propolis extract; Nippon Propolis Co., Ltd., Biomedix Co., Ltd., N-acetylglucosamine; Yaizu Suisan Chemical Co., Ltd.
・ Glucosamine hydrochloride; Koyo Chemical ・ Chondroitin sulfate; Marhanichiro Astaxanthin; Yamaha lycopene; Laico red ・ Isoflavone: Isomax AG40 (genistein dominant total aglycon 40%); Tokiwa plant chemistry laboratory, Isomax 80 (daidzein dominant total aglycon 50 %); Joban Institute of Plant Chemistry, French Coastal Pine Bark Extract (containing 60% or more proanthocyanidins); Toyo Shinyaku, 5% resveratrol red wine extract: Oriza oil, Mediens collagen (30% heat-denatured collagen type) Containing Collagen Peptide); Nippon Ham Central Research Laboratory, Cat's Claw Extract Powder;

Example 1
In the ratio shown in Table 1 (intake per day: mg / day), each component was mixed in a conventional manner, and after further mixing with an appropriate amount of excipients, compressed into tablets (average of 1 tablet) 2.5 g) was obtained.

Test example 1
Each of the chewable tablets obtained in Example 1 was ingested twice a day for 4 weeks (N = 10) using 10 mild metabolic syndrome Japanese patients aged 38 to 67 years as subjects. The diagnostic criteria for metabolic syndrome in Japan are the accumulation of visceral fat (waist circumference is 85cm or more for men, 90cm or more for women), and dyslipidemia including hypertension, hyperlipidemia or low HDL, and high It falls under at least two of the blood glucose levels.
During the intake period of chewable tablets, the use of new medicines and health foods (including supplements) and the introduction of dietary / exercise therapy and physical therapy were prohibited.
Before breakfast on the day of ingestion and before breakfast on the day after the end of ingestion, blood was collected from each subject, and the concentration of adiponectin in the blood was measured. The total adiponectin concentration was measured using a human adiponectin ELISA kit (manufactured by Otsuka Pharmaceutical Co., Ltd.), and the high molecular weight adiponectin concentration was determined by the method of Nakano et al. (Nakano Y et al., J Lipid Research, 2006: 47, 1572). -1582).
The results are shown in Table 2. The values in the table are the average rate of increase (%) 4 weeks after the start of the test when the measured value before the start of intake is taken as the baseline (100).

  As is apparent from Table 2, in the group (test group No. 1) ingesting artepilin C alone, although the amount of blood adiponectin increased, the rate of increase was slight, and N-acetylglucosamine, glucosamine hydrochloride There was no increase in blood adiponectin levels in the groups that received salt and chondroitin sulfate alone (test groups No. 17, 23, 29). In contrast, the intake of artepilin C and glucosamines or chondroitin sulfate increased both the amount of total adiponectin in blood and the amount of high molecular weight adiponectin. From this, it was confirmed that adiponectin secretion was promoted by ingesting a combination of artepilin C and glucosamines or chondroitin sulfate.

Example 2
In the ratios shown in Tables 3 and 4 (intake per day: mg / day), each component was mixed in a conventional manner, and after further mixing with an appropriate amount of excipients, the tablets were compressed into chewable tablets (1 An average grain size of 2.5 g) was obtained.

Test example 2
In the same manner as in Test Example 1, each chewable tablet was taken twice a day for 4 weeks (N = 10).
The results are shown in Tables 5 and 6. The values in the table are the average rate of increase (%) 4 weeks after the start of the test when the measured value before the start of intake is taken as the baseline (100).

  As is clear from Tables 5 and 6, 3,4-dihydroxy-5-prenylcinnamic acid, quercetin, kaempferide, p-coumaric acid, 4-dihydrocinnamoyloxy-3-prenylcinnamic acid, corosolic acid, resveratrol It was confirmed that secretion of adiponectin was promoted by ingesting a combination of isoflavone, astaxanthin, lycopene, anthocyanin, proanthocyanidin and glucosamines or chondroitin sulfate.

Example 3
In the ratio shown in Table 7 (intake per day: mg / day), each component was mixed by a conventional method, and after further mixing an appropriate amount of excipients, the mixture was compressed into tablets (average of 1 tablet) 2.5 g) was obtained.

Test example 3
In the same manner as in Test Example 1, each chewable tablet was taken twice a day for 4 weeks (N = 10).
The results are shown in Table 8. The values in the table are the average rate of increase (%) 4 weeks after the start of the test when the measured value before the start of intake is taken as the baseline (100).

As is clear from Table 8, in the group (test group No. 63) ingesting only type II collagen and cat's claw extract, no increase in the blood adiponectin level was observed. On the other hand, in addition to Artepilin C and N-acetylglucosamine, in addition to intake of type II collagen and cat's claw extract (test section No. 59-62), both the amount of total adiponectin in blood and the amount of high molecular weight adiponectin increase. However, this rate of increase was higher than when ingesting a combination of artepilin C and glucosamines. From this, it was confirmed that the adiponectin secretion promoting action was further enhanced by combining heat-denatured type II collagen and / or cats claw extract in addition to artepilin C or isoflavone and N-acetylglucosamine.

Example 4
Tablets (intake per day; average 5 mg per day, 200 mg per tablet) were prepared in the usual manner according to the following formulation. When the obtained tablets were ingested, the total blood adiponectin level and the high molecular weight adiponectin level increased.
(Unit: mg / day)
Loquat leaf extract (containing 1% corosolic acid) 50
N-acetylglucosamine 2000
Collagen peptide containing type II collagen 30% 666
Cat's claw extract (as total oxindole alkaloid) 3
Isoflavone (as total aglycone) 70
Excipient

Example 5
Tablets (intake per day; average 5 mg per day, 200 mg per tablet) were prepared in the usual manner according to the following formulation. When the obtained tablets were ingested, the total blood adiponectin level and the high molecular weight adiponectin level increased.
(Unit: mg / day)
Red wine extract containing 5% resveratrol 100
N-acetylglucosamine 2000
Type II collagen 30% collagen peptide 666
Cat's claw extract (as total oxindole alkaloid) 3
Isoflavone (as total aglycone) 70
Excipient

Example 6
Tablets (daily intake; 10 tablets 3 times a day, 1 tablet average 220 mg) were prepared in the usual manner according to the following formulation. When the obtained tablets were ingested, the total blood adiponectin level and the high molecular weight adiponectin level increased.
(Unit: mg / day)
Propolis extract powder 120
N-acetylglucosamine 2000
Type II collagen 30% collagen peptide 666
Cat's claw extract (as total oxindole alkaloid) 3
Isoflavone (as total aglycone) 70
Chondroitin sulfate 500
Royal Jelly 3000
Excipient

Claims (7)

(A) isoflavones, resveratrol and Rikopi down by Ri one or more selected antioxidants, and (B) glucosamine, one or more selected from N- acetylglucosamine and salts thereof a adiponectin secretion promoting food and drink for you containing glucosamine acids, 20~200mg said (a) and (B), as isoflavones total aglycone intake per day, resveratrol 1~15mg, A food or drink comprising lycopene in an amount of 5 to 100 mg and glucosamine in an amount of 50 to 5000 mg .   The food / drink for promoting adiponectin secretion according to claim 1, further comprising (C) chondroitin sulfate.   The adiponectin secretion according to claim 1 or 2, further comprising (D) one or more selected from collagen, cat's claw, royal jelly and 3-O-acetyl-keto-β-boswellic acid. Food and drink for promotion. Glucosamine is N-acetylglucosamine, The food-drinks for adiponectin secretion promotion of any one of Claims 1-3 characterized by the above-mentioned . (A) Arutepirin C, selected isoflavones, corosolic acid, resveratrol, one or more antioxidants selected Ri by lycopene and anthocyanins, and from (B) glucosamine, N- acetylglucosamine and salts thereof An adiponectin secretion promoter characterized by comprising one or more glucosamines as active ingredients. Furthermore, (C) chondroitin sulfate is contained, The adiponectin secretion promoter of Claim 5 characterized by the above-mentioned. The adiponectin secretion according to claim 5 or 6 , further comprising (D) one or more selected from collagen, cat's claw, royal jelly and 3-O-acetyl-keto-β-boswellic acid. Accelerator.